bloodwise.org.uk - Three new Birmingham research projects launched to beat blood cancer Updated 27 Sep 2018 Read more

Three new Birmingham research projects launched to beat blood cancer | Bloodwise

Bloodwise.org.uk Spined HTML

Three new Birmingham research projects launched to write-up thoroughbred cancer | Bloodwise Jump to navigation Bloodwise tropical Search unendingly by typing Bloodwise Enter your keywords ResearchWhy we fund research Our research Clinical trials Funding for researchers Information & supportBlood cancer Leukaemia Lymphoma Myeloma Other thoroughbred cancers Healthcare professionals Publications Community Get involvedEvents & challenges In your zone Corporate partnerships Philanthropy Fundraising ideas Volunteers ShopWell-nighusNews Media centre Leadership team Our experts Campaigning Jobs at Bloodwise DonateGive in memory Gift in Will Donate by post LoginJoin us © Bloodwise 2018 Login Login Username * Password * Forgot password?Remember me New to Bloodwise? Sign upIncreasinglyDonate Home › Three new Birmingham research projects launched to write-up thoroughbred cancer Posted by Bloodwise Three new Birmingham research projects launched to write-up thoroughbred cancer Posted by Bloodwise Updated 27 Sep 2018 New research to modernize survival rates for people with thoroughbred cancer is underway at the University of Birmingham, thanks to grants of nearly £850,000 from Bloodwise. The three variegated research projects are looking at ways to tailor intensive thoroughbred cancer treatment for individual patients, establish what goes wrong during cancer development, and investigate whether preventing worldwide infections could modernize survival rates for two warlike types of thoroughbred cancer.   Liz Burtally, Research Communications Manager at Bloodwise, said: “The University of Birmingham has a worldwide reputation for wearing whet research into new treatments for thoroughbred cancers. We are really thrilled well-nigh funding these three hugely promising new projects, which are searching for largest ways to treat thoroughbred cancer and we hope will make a real difference to people’s lives.” Investigating the link between infections and treatment-resistance In the first project, a team led by Professor Chris Bunce, Dr Farhat Khanim and Professor Mark Drayson will investigate whether infections make myelodysplastic syndrome (MDS) and vigilant myeloid leukaemia (AML) harder to treat.  Survival rates for these thoroughbred cancers are extremely poor, with fewer than two in 10 people with AML and three in 10 people with MDS surviving for longer than five years without diagnosis. Patients are moreover at risk of dying from worldwide infections considering they do not produce unbearable healthy immune cells, which are remoter reduced by the intensive chemotherapy used in treatment. The researchers are looking into a theory that these potentially fatal infections unquestionably moreover rationalization MDS and AML to wilt increasingly warlike and resistant to chemotherapy. They have once identified specific proteins released by yes-man that send ‘survival signals’ to the cancer cells to grow increasingly quickly. The team is delivering out experiments in the laboratory to study how these bacterial infections yo-yo the behaviour of patients’ cancer cells, and will test whether existing drugs can prevent this from happening. Dr Farhat Khanim Improving the effectiveness of stem lamina transplants In the second project at the University’s Institute of Immunology and Immunotherapy, Professor Paul Moss, Dr Jianmin Zuo and Dr Ram Malladi are leading a programme to develop new ways to modernize the effectiveness of stem lamina transplants, which can be the only endangerment of a long term cure for some thoroughbred cancer patients. A stem lamina transplant infuses donor thoroughbred stem cells into patients without they have undergone intensive chemotherapy to skiver any tumored cells and destroy their faulty unorthodoxy marrow. As well as re-establishing a healthy unorthodoxy marrow for the patient, donor white thoroughbred cells requite the patient a new immune system that can venery lanugo and skiver remaining cancer cells in the blood. However, virtually four in 10 patients with AML relapse within a year of their transplant.  The new immune system can moreover recognise the patient’s healthy tissue as ‘foreign’ and attacks these cells as well – causing life-threatening side effects. Professor Moss’s project is looking at ways to make this immune response increasingly thoughtfully controlled and effective, reducing side effects and the endangerment of relapse.  Prof Paul Moss Understanding the genetic faults that lead to thoroughbred cancer In the third project, Professor Jon Frampton at the University’s Institute of Cancer and Genomic Sciences is looking at how healthy thoroughbred lamina production goes wrong during thoroughbred cancer development. ‘MYB’ is a protein that is particularly important to the controlled minutiae of individual thoroughbred lamina types and is thought often to be essential in the minutiae of malignant thoroughbred disease. Professor Frampton believes that having lower levels of MYB puts people increasingly at risk of developing unrepealable thoroughbred diseases as they grow older.  It is possible that up to 10% of the population have naturally lower levels of MYB, and the project will seek to personize this and pinpoint what underlying effects this might have on thoroughbred cells. Understanding increasingly well-nigh how normal thoroughbred minutiae goes wrong and causes cancer could lead to new ways to treat the disease. Prof Jon Frampton FIND OUT MORE ABOUT THE RESEARCH THAT BLOODWISE FUNDS HERE   Leave this field zippo Stay updated with Bloodwise We’d like to tell you increasingly well-nigh how you can help us write-up thoroughbred cancer. Please sign-up to receive email updates well-nigh our work. View our Privacy Policy  Related blogs Through the eye of a needle: Molecular immunology and anti-cancer drugs Updated 03 Oct 2018 Read increasingly Three new Birmingham research projects launched to write-up thoroughbred cancer Updated 27 Sep 2018 Read increasingly Casualty star George Rainsford’s 5 tips for training for your next big run Updated 24 Sep 2018 Read increasingly Stand up for thoroughbred cancer: a history of Bloodwise’s relationship with spectacle Updated 02 Oct 2018 Read increasingly Another CAR-T treatment provisionally turned lanugo for use on NHS Updated 19 Sep 2018 Read increasingly A day in the life: Pedro Santos e Sousa, graft versus host disease researcher Updated 17 Sep 2018 Read increasingly Make secure payments with: Get in touchThoroughbredcancer support: 0808 2080 888Donations and fundraising: 0808 169 5155Head office: 0207 504 2200Media enquiries: ​0207 269 9019 Support us Get involvedMake a donationVisit the Bloodwise shop Follow us Our fundraising promise Feedback Terms & conditions Bloodwise, 39-40 Eagle Street, London, WC1R 4TH. A visitor limited by guarantee 738089 (registered in England and Wales). Registered soft-heartedness 216032 (England and Wales) SCO37529 (Scotland) © 2018